Omada Health (OMDA) is a Healthcare stock trading at $23.95 (as of 2026-08-25), with a market capitalization of $1.47B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Omada Health is a U.S.-based virtual-care provider offering clinically validated programs for chronic conditions like cardiometabolic disease, musculoskeletal care, and behavioral health—delivered digitally between doctor visits.
Understand Omada Health: how it makes money
Omada Health runs clinically validated digital care programs for chronic conditions (diabetes, hypertension, behavioral health) sold to health plans and employers as a member benefit. Revenue is payer-funded and delivered through a virtual coach-and-clinician model, so the cost of serving each additional member stays low as the platform scales.
Revenue is set by payer contracts per member rather than patient willingness to pay; the 73% gross margin comes from digital delivery of care, while the 4% operating margin reflects coach and clinician labor that must dilute as the member base compounds.
Business quality (Mixed): Promising unit economics (41% incremental EBITDA margin) sit on top of a 73% gross margin, but the 4% operating margin and negative ROE say the cost side has not yet caught up to the revenue side. This is an early-stage operating-leverage story, not yet a cash-growth machine.
Bull case
HCSC opens 1.5M new lives: HCSC added 1.5 million covered lives across three states for 2027, a concrete payer-level pipeline that extends Omada's addressable member pool well beyond its current state footprint.
41% incremental margin proves leverage: Management confirmed the platform generates 41% incremental EBITDA margin on each additional member, meaning the digitally delivered care model is genuinely converting scale into operating-profit growth rather than just top-line growth.
Cardiometabolic mix lifts pricing power: Diabetes and hypertension programs grew over 50% and carry higher per-member pricing with longer engagement duration, shifting the revenue mix toward higher-value, stickier members and improving lifetime-value economics per plan contract.
Bear case
GLP-1 coverage decisions unresolved: Employer and plan decisions on whether to cover GLP-1 weight-loss therapies remain uncertain, creating direct demand risk for the 150,000 members currently enrolled in that program and the growth narrative tied to it.
Hiring front-loads second-half opex: Management expects front-loaded coach and clinician hiring to keep second-half operating expenses elevated, which will compress the already thin 4% operating margin before scale fully absorbs the incremental labor costs.
H2 growth faces seasonal drag: Second-half revenue growth faces seasonal moderation and difficult year-over-year comparisons, making it challenging to sustain the 43% YoY pace seen in Q2 through the full fiscal year.